PMC44 EXPERTS' JUDGEMENT ON PATIENT-CENTRED COORDINATED CARE  by Mühlbacher, AC et al.
13th Euro Abstracts A337
satisfaction domains exhibited the strongest signiﬁ cant results amongst all three tests. 
However, while the convenience domain exhibited strongly signiﬁ cant measurement 
equivalence for the CTT, it only exhibited signiﬁ cant results for the SEM and DIF. 
CONCLUSIONS: While all three methods indicated the same overall results, there is 
some suggestion of differing sensitivity amongst the tests.
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OBJECTIVES: Delivering care coordination services is often described as the key to 
effectively meet patients’ needs and expectations. Patient empowerment and patient 
participation is highly discussed and postulated, but there is a lack of knowledge of 
how to design patient-centered coordinated care. This study intends to provide health 
policy and decision-makers with a comprehensive assessment on experts’ priorities in 
the relative value of different dimensions of coordinated care. METHODS: A ques-
tionnaire with 88 items was conducted with N = 251 health care experts. Exploratory 
and conﬁ rmatory factor analysis was performed using SPSS©18. The number of factors 
to be retained was controlled by Kaiser’s criterion (eigenvalues above 1), validation 
of the scree plot, and the interpretability of the items. Cronbach’s alpha was used to 
assess the internal consistency of the subscales identiﬁ ed. RESULTS: The exploratory 
factor analysis leaded to 25 factors. After analyzing the screeplots and qualitative 
results conﬁ rmatory factor analysis was computed for an 8 factor solution accounting 
for 42,828 % of the total variance and with KMO of 0.723. Cronbach alpha reliability 
coefﬁ cients were computed for each of the sub-scales and ranged between 0.849 and 
0.745. Based on the existing literature and the analysis conducted, coordinated care 
could be differentiated into eight dimensions: access, knowledge transfer, technical 
care, interpersonal care, patient-centeredness, continuity, infrastructure and participa-
tion in social life. CONCLUSIONS: The aim of the study was to structure the key 
attributes for future stated preference research. Differences in experts’ judgment and 
patients’ perspective will be analyzed in upcoming research. If expectations of stake-
holders are taken into account adequately, it can be assumed that this will increase 
the motivation to participate in and the satisfaction with coordinated care 
programs.
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OBJECTIVES: While eClinical Forum’s 2009 survey ﬁ ndings suggest that electronic 
data capture (EDC) is used in 58% of clinical trials, little is known about the use of 
electronic patient reported outcome (ePRO) technologies for data collection. The 
purpose of this survey study was to describe the experiences and perceptions regarding 
use of ePRO as reported by pharmaceutical, biotech, medical device, and other indus-
try professionals. METHODS: Global industry professionals were invited to complete 
a web-based survey ﬁ elded in early 2010. Participants were asked about their profes-
sional demographics, PRO and ePRO experiences, as well as challenges and advan-
tages of using ePROs. Responses were analyzed descriptively. RESULTS: To date, 153 
industry professionals completed the survey. Forty-four percent of respondents were 
from pharmaceutical companies, followed by other (41%), biotech (10%) and medical 
device (6%). Forty nine percent had previous PRO study experience among which 
51% had prior ePRO experience. Among respondents using a PRO measure in an 
international study, 43% used ePRO for data collection. Hand-held device (tablet, 
PDA) was the most common ePRO technology (42%), followed by interactive web-
response (29%) or voice-response (29%). Reported advantages of ePROs include 
accuracy of information collected (79%), increased compliance (73%), and ease of 
use (64%); challenges include patient training (65%), study start-up costs (64%) or 
time (54%), and patient burden (54%). Validation of PRO for EDC use was an 
important factor when considering paper-based versus ePRO data collection (21%). 
Among those responding, 26% indicated they used ePRO data collection in >50% of 
their clinical trials, and 82% strongly agreed/agreed they would use ePRO in future 
studies. CONCLUSIONS: Preliminary results from this survey suggest that among 
those who use PRO measures in studies, the percent of industry professionals using 
ePROs is similar to the overall percent of industry using EDC as a data collection 
method in clinical trials.
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OBJECTIVES: PRO measures use a variety of response scales/options. These vary 
according to the type of measure, and can include frequency (time-based) scales, 
severity (intensity) scales, visual analogue scales (VAS) and levels of agreement. The 
translation and linguistic validation of response options can cause semantic or con-
ceptual difﬁ culties. This research aims to identify the issues raised during the transla-
tion of some response scales, with the aim of aiding the translatability of response 
options. METHODS: Examples of issues in the translation and linguistic validation 
of response options were collected from past Oxford Outcomes projects. Those 
response options which were problematic across PRO measures and languages were 
evaluated. RESULTS: Numerous cultural and linguistic issues became apparent 
throughout the translation process which require careful attention being paid to the 
response options during the translation and linguistic validation process: /Some mid-
scale words used in severity scales are particularly difﬁ cult to translate, e.g. rather, 
somewhat. Two response options on a scale, e.g. rather conﬁ dent, fairly conﬁ dent can 
be very small and unclear. /Frequency scales (how often . . .) are often translated as 
“how many times,” in some languages (particularly Indian). When using “level of 
agreement” scales the word “strongly” often proves problematic as some languages 
ﬁ nd it difﬁ cult to express levels of agreement. CONCLUSIONS: Various issues with 
response options were recognised during the linguistic validation of a considerable 
number of PRO measures. a full translation and linguistic validation procedure can 
help to overcome such problems, but care should be taken when choosing response 
scales during the development of PRO measures. In general, response options, which 
are particularly close in meaning, e.g. somewhat, rather, are usually more problematic 
to translate than those with clear parameters, e.g. never, rarely, sometimes, often, 
always.
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OBJECTIVES: Capturing patient-reported outcomes (PRO) via the web can be an 
efﬁ cient tool in larger-population clinical studies. Enabling patients to use their own 
computers means that web-based PROs are administered to patients on a wider variety 
of screen sizes and resolutions. As indicated in the recent ISPOR ePRO Report by 
Coons SJ, et al, this creates an issue of ensuring equivalency of the instruments across 
all screen sizes. This research describes a practical approach for maintaining validity 
of instruments when patients use their own computer. It aims to evaluate whether the 
PRO is presented as intended on various screen sizes and browsers. The research also 
takes into consideration variability of computer infrastructure in different geographi-
cal areas, as this is a major factor limiting web-based data collection. METHODS: 
The EuroQoL EQ-5D was programmed for use on smaller screens and scaled up to 
larger sizes and put into an ongoing usability testing study in the US, UK, Spain, 
Finland, Singapore, and China for sufﬁ cient coverage of languages and technologies. 
The sample size is 30 healthy volunteers. Screen sizes varied from small mini laptop 
screens to large LCD screens (9″ to 24″). RESULTS: Early results show that the 
questionnaire ﬁ ts on all screens without a need for patients to scroll either in left-right 
or up-down directions. On 15,4″ screen, the questionnaire occupies 71% of the screen 
versus 57% on a 24″ display. The difference in relative size is 19%, which indicates 
that the questionnaire remains usable even if the screen size increases by 56%. Further 
results are forthcoming. CONCLUSIONS: As the presentation of the PRO is the same 
on all screens, conducting psychometric validation may be more straightforward. In 
addition, ﬁ nding a method to ensure one PRO design works on all computers is a 
major factor in conducting global studies efﬁ ciently.
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OBJECTIVES: In clinical trials, the capture of patient-reported outcome (PRO) data 
has increased over the past decade. Regulatory guidelines, including the EMEA’s 
concern of Health-Related Quality of Life (HRQL) measurements and the FDA’s 
emphasis on PRO data to support labeling claims, have led to a greater inclusion of 
PRO as clinical trial endpoints. As sponsors include more PRO measurements, many 
turn to electronic PRO (ePRO) data capture. This presentation summarizes literature 
from the last 9 years to report changes in the use of ePRO including projections for 
future applications in clinical trials, disease management and health policy. 
METHODS: This presentation is a synthesis of literature in peer reviewed journals 
regarding ePRO from 2000 to 2010. Key search terms include “patient reported 
outcomes”, “electronic patient reported outcomes”, “electronic diaries”, “interactive 
voice response system”, “interactive web response system” and “digital pen”. The 
literature review made use of meta-databases such as PubMed and Medline. RESULTS: 
The use of ePRO has increased since a decade ago, due to greater movement in health 
care towards electronic solutions and to regulatory emphasis on PRO collection in 
clinical trials. The presentation will detail how ePRO is being used and provide a 
synthesis of recommendations for future ePRO use based on the literature. The session 
will examine the indications and therapeutic areas, population types, and applications 
of ePRO within health care and will review evidence showing whether ePRO data 
quality is higher than that of data captured using paper methods. CONCLUSIONS: 
The presentation deals with the evolving questions of ePRO—projected limitations and 
actual scope of experience with ePRO. Due to literature emphasis, the presentation will 
focus on clinical trials but will also examine other health care ﬁ elds such as disease 
management and health policy. Attendees will learn about the evolution of ePRO and 
forthcoming directions and receive a bibliography of current literature.
